|
|
|
|
|
|
| Abstract Search | Browse Program and Abstracts | Schedule-at-a-Glance | Conference Mission & Sponsors | Program Committee | Contact Us |
| # | Title |
|---|---|
| 45 | The Multispecific B- and T-Cell Responses Induced in Humans by an HIV-1 Lipopeptide Vaccine Can Be Sustained over a Period of up to Two Years
H. Gahéry-Ségard*1, G. Pialoux2, S. Figueiredo1, M. Sureneau1, C. Igéa1, J.-P. Lévy1, H. Gras-Masse3, and J.-G. Guillet1 1 Hosp. Cochin, INSERM U445, Paris, France; 2 Hosp. Rothschild, Paris, France; and 3CNRS URA1309, Inst. Pasteur de Lille, France |
| 46 | Phase I Clinical Trial of a Multivalent HIV-1 Peptide Vaccine Containing B and T Epitopes Formulated in Incomplete Freund’s Adjuvant
B. Graham*1, J. Ottinger2, K. Weinhold2, G. Ferrari2, M. Keefer3, J. McElrath4, and B. Haynes2 1Vaccine Res. Ctr., NIH, Bethesda, MD, USA; 2Duke Univ. Med. Ctr., Durham, NC, USA; 3Rochester Univ. Sch. of Med. and Dentistry, NY, USA; and 4Univ. of Washington Sch. of Med. at Seattle, USA |
| 47 | Safety Profile of Preventive Canarypox-Vectored (ALVAC) HIV-1 Vaccines Tested in the US: 1993(2001
M. Keefer*1, R. El Habib2, and the NIAID HIV Vaccine Trials Network 1Univ. of Rochester Med. Ctr., NY, USA and 2Aventis Pasteur, Marcy l’Etoile, France |
| 48 | Immunogenicity of Canarypox (ALVAC)-HIV-1 Candidate Vaccines in Normal Volunteers
R. Dolin*1, R. El Habib2, and the NIAID HIV Vaccine Trials Network (HVTN) 1Harvard Med. Sch., Boston, MA, USA and 2Aventis Pasteur, Marcy l'Etoile, France |